Edition:
India

La Jolla Pharmaceutical Co (LJPC.OQ)

LJPC.OQ on NASDAQ Stock Exchange Capital Market

28.56USD
12:48am IST
Change (% chg)

$-1.90 (-6.24%)
Prev Close
$30.46
Open
$30.71
Day's High
$30.87
Day's Low
$28.40
Volume
118,055
Avg. Vol
128,574
52-wk High
$39.26
52-wk Low
$16.71

Chart for

About

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant... (more)

Overall

Beta: 1.70
Market Cap(Mil.): $794.45
Shares Outstanding(Mil.): 22.12
Dividend: --
Yield (%): --

Financials

BRIEF-Broadfin Capital Reports 5 Percent Passive Stake In La Jolla Pharmaceutical - SEC Filing‍​

* BROADFIN CAPITAL LLC REPORTS 5 PERCENT PASSIVE STAKE IN LA JOLLA PHARMACEUTICAL CO AS OF JAN 9 - SEC FILING‍​ Source text: (http://bit.ly/2D4NbRm) Further company coverage:

12 Jan 2018

BRIEF-La Jolla Pharmaceutical Says Cash Resources Are Expected To Fund Co Into Second Half Of 2018

* LA JOLLA PHARMACEUTICAL SAYS CASH RESOURCES ARE EXPECTED TO FUND CO INTO SECOND HALF OF 2018 - SEC FILING Source text for Eikon: (http://bit.ly/2BTfmOK) Further company coverage:

30 Dec 2017

FDA approves La Jolla's low blood pressure drug

La Jolla Pharmaceutical said on Thursday the U.S. Food and Drug Administration had approved its drug, Giapreza, to treat dangerously low blood pressure.

22 Dec 2017

FDA approves La Jolla's low blood pressure drug

Dec 21 La Jolla Pharmaceutical said on Thursday the U.S. Food and Drug Administration had approved its drug, Giapreza, to treat dangerously low blood pressure.

22 Dec 2017

BRIEF-La Jolla Says FDA Approved Drug To Treat Critically Low Blood Pressure

* U.S. FOOD AND DRUG ADMINISTRATION SAYS APPROVED GIAPREZA (ANGIOTENSIN II) TO TREAT DANGEROUSLY LOW BLOOD PRESSURE

22 Dec 2017

BRIEF-La Jolla Pharmaceutical Initiates Multicenter, Randomized, Phase 2 Clinical Study Of LJPC‑401

* INITIATION OF MULTICENTER, RANDOMIZED, PHASE 2 CLINICAL STUDY OF LJPC-401 IN PATIENTS WITH HEREDITARY HEMOCHROMATOSIS Source text for Eikon: Further company coverage:

18 Dec 2017

BRIEF-La Jolla Pharma files for mixed shelf of up to $150 mln ‍​

* Files for mixed shelf of up to $150 million - SEC filing‍​ Source text : [http://bit.ly/2zK9cPg] Further company coverage:

28 Oct 2017

BRIEF-La Jolla reports Q3 loss $1.19/shr

* La Jolla Pharmaceutical Company announces financial results for the three and nine months ended September 30, 2017 and recent corporate progress

27 Oct 2017

BRIEF-Prudential Financial reports 10.1 pct passive stake ​in La Jolla Pharmaceutical

* Prudential Financial Inc reports 10.1 percent passive stake ​in La Jolla Pharmaceutical Co as of Sept 30 - sec filing ‍ Source text : [http://bit.ly/2g07Ckv] Further company coverage:

10 Oct 2017

BRIEF-La Jolla Pharmaceutical Co announces intent to submit Marketing Authorization Application for LJPC-501

* La Jolla Pharmaceutical Company announces intent to submit Marketing Authorization Application for LJPC-501 in the third quarter of 2018 Source text for Eikon: Further company coverage:

25 Sep 2017

Competitors

  Price Chg
Galectin Therapeutics Inc (GALT.OQ) $5.63 -0.24
Merck & Co., Inc. (MRK.N) $62.45 +3.79
Roche Holding Ltd. (ROG.S) CHF236.00 -8.40
Roche Holding Ltd. (RO.S) CHF239.40 -8.20
Novartis AG (NOVN.S) CHF83.56 +0.02
Celltrion, Inc. (068270.KQ) ₩347,400.00 -2,600.00
Kyowa Hakko Kirin Co Ltd (4151.T) ¥2,198 -7.00
Astellas Pharma Inc (4503.T) ¥1,438 +2.00

Earnings vs. Estimates